SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH M impact

CELZ: Expands ADAPT Trial

Creative Medical Technology receives FDA clearance to expand its ADAPT clinical trial evaluating CELZ-201 for chronic lower back pain associated with degenerative disc disease

CELZ

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.